Edition:
United States

Bison Capital Acquisition Corp (BCAC.OQ)

BCAC.OQ on NASDAQ Stock Exchange Capital Market

10.28USD
16 Oct 2018
Change (% chg)

-- (--)
Prev Close
$10.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,511
52-wk High
$10.30
52-wk Low
$9.67

Latest Key Developments (Source: Significant Developments)

Bison Capital Acquisition Reports Terms of Xynomic deal termination
Thursday, 13 Sep 2018 06:13am EDT 

Sept 13 (Reuters) - Bison Capital Acquisition Corp ::BISON CAPITAL ACQUISITION - XYNOMIC WILL BE OBLIGATED TO PAY CO'S SPONSOR A $4.5 MILLION TERMINATION FEE IF DEAL TERMINATED UNDER CERTAIN CONDITIONS.  Full Article

Bison Capital Acquisition, Xynomic Pharmaceuticals Sign Definitive Merger Agreement
Wednesday, 12 Sep 2018 09:49pm EDT 

Sept 12 (Reuters) - Bison Capital Acquisition Corp ::Bison Capital Acquisition Corp. AND XYNOMIC PHARMACEUTICALS, INC. ANNOUNCE SIGNING OF DEFINITIVE MERGER AGREEMENT.UPON COMPLETION OF MERGER, XYNOMIC WILL BECOME A WHOLLY-OWNED SUBSIDIARY AND OPERATING BUSINESS OF BCAC.BISON CAPITAL ACQUISITION-AGGREGATE MERGER CONSIDERATION WILL CONSIST OF CLOSING CONSIDERATION OF $350 MILLION IN BCAC SHARES, SUBJECT TO CERTAIN ADJUSTMENTS.UPON COMPLETION OF MERGER BCAC WILL CHANGE ITS NAME TO "XYNOMIC PHARMACEUTICALS HOLDINGS, INC.UNDER TERMS OF AGREEMENT, CO WILL RE-DOMESTICATE FROM BRITISH VIRGIN ISLANDS TO DELAWARE PRIOR TO MERGER.BISON CAPITAL ACQUISITION- AGGREGATE MERGER CONSIDERATION WILL CONSIST OF EARNOUT CONSIDERATION OF ADDITIONAL $100 MILLION IN BCAC SHARES.MERGER CONSIDERATION WILL BE PAYABLE ENTIRELY IN COMMON STOCK OF BCAC AT A VALUE OF $10.15 PER SHARE.EXECUTIVES OF XYNOMIC ARE EXPECTED TO REMAIN AS EXECUTIVES OF COMBINED COMPANY.  Full Article

No consensus analysis data available.